Spectral Medical (EDT) Q4 2024 earnings summary

Executive summary

• Achieved significant clinical and operational progress in 2024, nearing full enrollment in the pivotal Tigris Phase III trial for PMX in endotoxic septic shock.

• Robust patient enrollment in Tigris, with 154 randomized and only a few more needed for regulatory submission.

• Strengthened commercialization partnership with Vantive, including completion of the PrisMax sub-study.

Financial highlights

• Revenue for Q4 2024 was $645,000, up from $365,000 in Q4 2023; full-year 2024 revenue rose 43% to $2,286,000.

• Operating expenses for Q4 2024 were $(2,513,000), a decrease due to lower fair value adjustment on derivative liability.

• Full-year operating costs increased to $17,681,000, mainly from higher interest expenses and foreign exchange loss.

• Loss from continuing operations for 2024 was $15,395,000, nearly flat year-over-year.

• Ended 2024 with $2,988,000 in cash and 284,316,207 shares outstanding.

Outlook and guidance

• Full Tigris trial enrollment expected within weeks, enabling FDA submission and potential approval.

• Entering a regulatory-focused phase with updates on the PMX pathway and funding solutions anticipated soon.

• Commercial launch plans for PMX are advancing, leveraging Vantive’s ICU device footprint.